Value of serum microRNA-184 and microRNA-451a expression in predicting recurrent metastasis after radical surgery of patients with non-small cell lung cancer in stage Ⅰ to ⅡA

FAN Jun; WEI Ke; LUO Jinhua; XUE Lei

doi:10.7619/jcmp.20240421

Journal of Clinical Medicine in Practice > 2024 > 28(13): 1-6. > DOI: 10.7619/jcmp.20240421

FAN Jun, WEI Ke, LUO Jinhua, XUE Lei. Value of serum microRNA-184 and microRNA-451a expression in predicting recurrent metastasis after radical surgery of patients with non-small cell lung cancer in stage Ⅰ to ⅡA[J]. Journal of Clinical Medicine in Practice, 2024, 28(13): 1-6. DOI: 10.7619/jcmp.20240421

Citation:

PDF (993 KB)

Value of serum microRNA-184 and microRNA-451a expression in predicting recurrent metastasis after radical surgery of patients with non-small cell lung cancer in stage Ⅰ to ⅡA

Department of Thoracic Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210000

More Information

Received Date: January 22, 2024
Revised Date: April 07, 2024
Available Online: July 19, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the value of serum microRNA (miRNA)-184 and miR-451a expression in predicting recurrent metastasis after radical resection of stage Ⅰ to ⅡA non-small cell lung cancer (NSCLC).
Methods
A total of 203 patients with radical resection of stage Ⅰ to ⅡA NSCLC in the hospital from January 2020 to October 2021 were selected as NSCLC group. According to the recurrence and metastasis status during the 2-year follow-up, they were divided into recurrence and metastasis group with 30 cases and non-recurrence and metastasis group with 173 cases. Additionally, 87 healthy volunteers with physical examinations in the same period were selected as control group. Real-time quantitative polymerase chain reaction was used to detect serum expression of miR-184 and miR-451a. Multivariate Logistic regression model was used to analyze the factors affecting recurrence and metastasis after radical resection of stage Ⅰ to ⅡA NSCLC. Receiver operating characteristic (ROC) curve was used to analyze the value of serum miR-184 and miR-451a expression in predicting recurrence and metastasis.
Results
Compared with the control group, the expression of serum miR-184 and miR-451a in the NSCLC group decreased significantly (P < 0.05). After 2 years of follow-up, the recurrence and metastasis rate of 203 patients with stage Ⅰ to ⅡA NSCLC was 14.78% (30/203). Compared with the non-recurrence and metastasis group, the expression of serum miR-184 and miR-451a in the recurrence and metastasis group decreased significantly (P < 0.05). The independent risk factors for recurrence and metastasis after radical resection of stage Ⅰ to ⅡA NSCLC were stage ⅡA, poor differentiation and postoperative adjuvant chemotherapy, while the independent protective factors were increased miR-184 and miR-451a expression (P < 0.05). The area under the curve (AUC) of the combined prediction of serum miR-184 and miR-451a expression for recurrence and metastasis after radical resection of stage Ⅰ to ⅡA NSCLC was 0.868, which was greater than 0.784 and 0.781 of serum miR-184 and miR-451a expression alone (P < 0.05).
Conclusion
The serum miR-184 and miR-451a expression in patients with stage Ⅰ to ⅡA NSCLC is low and closely related to recurrence and metastasis after radical resection. The combined detection of serum miR-184 and miR-451a has a high predictive value for recurrence and metastasis after radical resection of stage Ⅰ to ⅡA NSCLC.
- non-small cell lung cancer,
- radical resection,
- microRNA-184,
- microRNA-451a,
- recurrence and metastasis

FullText(HTML)

References (31)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590.
[3]	中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会, 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2022版)[J]. 中华医学杂志, 2022, 102(48): 3819-3835.
[4]	周来燕, 卢铀. 早期非小细胞肺癌术后复发的预测因子[J]. 临床肿瘤学杂志, 2020, 25(7): 650-655.
[5]	袁月, 李琳. 非小细胞肺癌根治术后复发转移危险因素研究进展[J]. 中国医学前沿杂志: 电子版, 2023, 9(1): 40-45.
[6]	张吉瑞, 汤佳琦, 夏铀铀. miRNA在非小细胞肺癌诊断和治疗中的研究进展[J]. 癌症进展, 2020, 18(1): 4-7, 25.
[7]	CHEN P Y, LI X D, MA W N, et al. Comprehensive Transcriptomic Analysis and Experimental Validation Identify lncRNA HOXA-AS2/miR-184/COL6A2 as the Critical ceRNA Regulation Involved in Low-Grade Glioma Recurrence[J]. Onco Targets Ther, 2020, 13: 4999-5016.
[8]	YOSHIKAWA Y, FUKUNAGA M, TAKAHASHI J, et al. Identification of the minimum combination of serum microRNAs to predict the recurrence of colorectal cancer cases[J]. Ann Surg Oncol, 2023, 30(1): 233-243.
[9]	王蕾, 欧宗兴. 血清外泌体miR-184在非小细胞肺癌中的表达水平及其诊断效能[J]. 兰州大学学报: 医学版, 2018, 44(3): 31-36.
[10]	LI C Y, YIN Y H, LIU X, et al. Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance[J]. Oncotarget, 2017, 8(15): 24564-24578.
[11]	AMIN M B, MAHUL B, AMIN S B, et al. American joint committee on cancer staging manual[M]. 8th ed. New York: Springer, 2017: 103-111.
[12]	中华医学会呼吸病学分会. 早期肺癌诊断中国专家共识(2023年版)[J]. 中华结核和呼吸杂志, 2023, 46(1): 1-18.
[13]	苏芳, 石志浩, 赵静, 等. 血浆lncRNA-SNHG20和lncRNA-TCF7表达对非小细胞肺癌的诊断价值研究[J]. 实用临床医药杂志, 2023, 27(7): 35-39, 92.
[14]	郑昌言, 蒋家豪, 宋戈, 等. 靶向人表皮生长因子受体3治疗非小细胞肺癌的研究进展[J]. 药学进展, 2023, 47(9): 706-716.
[15]	中国肺癌早诊早治专家组, 中国西部肺癌研究协作中心. 中国肺癌低剂量CT筛查指南(2023年版)[J]. 中国肺癌杂志, 2023, 26(1): 1-9.
[16]	罗鑫, 孙继红, 李佳妮, 等. 新一代表皮生长因子受体-酪氨酸激酶抑制剂在非小细胞肺癌中的研究进展[J]. 药学进展, 2022, 46(05): 369-378.
[17]	胡锡麟, 田凯华. 表观遗传修饰调控微小RNA表达在肺癌中的研究进展[J]. 中国肺癌杂志, 2020, 23(7): 582-588.
[18]	李少儒, 李燕, 刘珊, 等. LncRNA SNHG11通过抑制miR-184/CARM1信号轴促进卵巢癌生长[J]. 天津医药, 2023, 51(6): 561-567.
[19]	辛欣, 綦成, 王昕. miR-184靶向ZNRF3调控口腔鳞状细胞癌增殖和转移的分子机制[J]. 中国老年学杂志, 2021, 41(5): 1075-1080.
[20]	LIN T C, LIN P L, CHENG Y W, et al. MicroRNA-184 deregulated by the microRNA-21 promotes tumor malignancy and poor outcomes in non-small cell lung cancer via targeting CDC25A and c-Myc[J]. Ann Surg Oncol, 2015, 12(Suppl 3): S1532- S1539.
[21]	郎博娟, 马金阳, 胡余昌, 等. 胶质瘤中microRNA-184的表达及其预后价值[J]. 肿瘤防治研究, 2015, 42(5): 483-487.
[22]	LIU W, MA C, XU H, et al. miR-184-5p inhibits cell proliferation, invasion and predicts prognosis of clear cell renal cell carcinoma by targeting NUS1 dehydrodolichyl diphosphate synthase subunit: Results from large-scale comprehensive identification and validation[J]. J Cancer, 2022, 13(5): 1398-1409.
[23]	JIA L, SHI Y, WEN Y, et al. The roles of TNFAIP2 in cancers and infectious diseases[J]. J Cell Mol Med, 2018, 22(11): 5188-5195.
[24]	杨华军, 何金英, 王广, 等. miR-184靶向TNFAIP2调控肺癌血管新生的分子机制[J]. 中国老年学杂志, 2023, 43(8): 1948-1952.
[25]	吴伟川, 刘磊峰, 门东海, 等. miR-451a通过下调巨噬细胞移动抑制因子抑制胶质瘤增殖的研究[J]. 重庆医学, 2022, 51(10): 1649-1653, 1659.
[26]	刘曦, 王海东, 吴蔚, 等. miR-451a/KIF2A轴对食管鳞状细胞癌顺铂耐药的影响[J]. 中华实用诊断与治疗杂志, 2022, 36(2): 144-150.
[27]	GAO B, LI R, SONG X, et al. miR-139-5p and miR-451a as a diagnostic biomarker in LUSC[J]. Pharmgenomics Pers Med, 2023, 8(16): 313-323.
[28]	姜经航, 郭哲, 杨浩洁, 等. 肝细胞癌根治术后早期复发相关microRNAs的筛选[J]. 中国癌症防治杂志, 2014(3): 224-229.
[29]	TAKAHASI K, IINUMA H, WADA K, et al. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(2): 155-161.
[30]	SHEN Y Y, CUI J Y, YUAN J, et al. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2[J]. Eur Rev Med Pharmacol Sci, 2018, 22(17): 5554-5561.
[31]	CUI J, WANG J, SHEN Y, et al. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC[J]. Genes Genomics, 2021, 43(2): 105-114.

Cited By

Get Citation

PDF

XML

Article views (127) PDF downloads (24)

Turn off MathJax

Article Contents

Abstract

References

Value of serum microRNA-184 and microRNA-451a expression in predicting recurrent metastasis after radical surgery of patients with non-small cell lung cancer in stage Ⅰ to ⅡA

Abstract

References

Catalog

Export File

Citation

Format

Content